Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology.

Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology.
复制标题

DOI:
10.1021/cn100051m
复制
发表时间:
2010-10-20
影响因子:
5
通讯作者:
Conn, P. Jeffrey
Conn, P. Jeffrey
中科院分区:
医学3区
文献类型:
--
作者:
Hammond, Alexis S.;Rodriguez, Alice L.;Townsend, Steven D.;Niswender, Colleen M.;Gregory, Karen J.;Lindsley, Craig W.;Conn, P. Jeffrey

文献摘要

参考文献

被引文献

相似文献

我们以前发现了代谢型谷氨酸受体亚型5(mGlu 5)的正变构调节剂(PAM),称为4 N-{4-氯-2-[(1,3-二氧代-1,3-二氢-2H-异吲哚-2-基)甲基]苯基}-2-羟基苯甲酰胺(CPPHA),其通过mGlu 5上的新变构位点来增强受体活化,该变构位点不同于经典的mGlu 5负变构调节剂(NAM)MPEP变构位点。然而,一个浅的结构活性关系(SAR),差的理化性质,并在大鼠mGlu 5弱PAM活性限制了CPPHA的效用,探索在非MPEP网站的mGlu 5变构激活。因此,我们进行了功能性高通量筛选(HTS)并鉴定了一种新型mGlu 5 PAM苯甲酰胺支架,例如VU 0001850(EC 50 = 1.3 μM,106%Glumax)和VU 0040237(EC 50 = 350 nM,84%Glu Max)。迭代平行合成方法递送了22种类似物,优化了mGlu 5 PAM活性以提供VU 0357121(EC 50 = 33 nM,92%Glumax),并且还揭示了第一个非MPEP位点中性变构配体(VU 0365396)。与CPPHA一样,基于放射性配体结合研究,这类PAM似乎不结合在MPEP变构位点。此外,诱变研究表明,VU 0357121和相关类似物结合到mGlu 5上的一个尚未表征的变构位点,不同于CPPHA,但与MPEP位点具有功能性相互作用。
We previously discovered a positive allosteric modulator (PAM) of the metabotropic glutamate receptor subtype 5 (mGlu5) termed 4 N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) that elicits receptor activation through a novel allosteric site on mGlu5, distinct from the classical mGlu5 negative allosteric modulator (NAM) MPEP allosteric site. However, a shallow structure−activity relationship (SAR), poor physiochemical properties, and weak PAM activity at rat mGlu5 limited the utility of CPPHA to explore allosteric activation of mGlu5 at a non-MPEP site. Thus, we performed a functional high-throughput screen (HTS) and identified a novel mGlu5 PAM benzamide scaffold, exemplified by VU0001850 (EC50 = 1.3 μM, 106% Glumax) and VU0040237 (EC50 = 350 nM, 84% Glu Max). An iterative parallel synthesis approach delivered 22 analogues, optimized mGlu5 PAM activity to afford VU0357121 (EC50 = 33 nM, 92% Glumax), and also revealed the first non-MPEP site neutral allosteric ligand (VU0365396). Like CPPHA, PAMs within this class do not appear to bind at the MPEP allosteric site based on radioligand binding studies. Moreover, mutagenesis studies indicate that VU0357121 and related analogues bind to a yet uncharacterized allosteric site on mGlu5, distinct from CPPHA, yet share a functional interaction with the MPEP site.
DOI: 10.2174/1568007023339544
发表时间: 2002-01-01
影响因子: 3
作者:
Marino, M. J.;Conn, P. Jeffrey
通讯作者: Conn, P. Jeffrey
DOI: 10.1016/j.tips.2008.10.006
发表时间: 2009-01
影响因子: 13.8
作者:
Conn PJ;Lindsley CW;Jones CK
通讯作者: Jones CK
DOI: 10.1016/s0028-3908(99)00082-9
发表时间: 1999-10-01
期刊: NEUROPHARMACOLOGY
影响因子: 4.7
作者:
Gasparini, F;Lingenhöhl, K;Kuhn, R
通讯作者: Kuhn, R
DOI: 10.1124/mol.107.041053
发表时间: 2008-04-01
影响因子: 3.6
作者:
Niswender, Colleen M.;Johnson, Kari A.;Weaver, C. David
通讯作者: Weaver, C. David